Xie Yanming (Chief Physician)
Discipline: Clinical Integrative Medicine
Position: Director
Affiliation: Institute of Clinical Basic Medicine of Traditional Chinese Medicine, Chinese Academy of Traditional Chinese Medicine
Address: No. 16, South Small Street, Dongzhimen, Dongcheng District, Beijing
Specialist Profile
Institute of Clinical Basic Medicine of Chinese Medicine, Chinese Academy of Traditional Chinese Medicine
Part-time positions
Executive Chairman of the World Federation of Chinese Medicine Societies (WFCMS) Committee on Postmarketing Evaluation of Traditional Chinese Medicine; Vice Chairman of the WFCMS Committee on Geriatrics; Vice Chairman of the WFCMS Committee on Osteoporosis; Vice Chairman of the Chinese Society of Traditional Chinese Medicine (CCM) Branch on Brain Diseases
Research Direction
1 Chronic disease management: research on the management model and effects of common chronic diseases in the community such as hypertension, diabetes, stroke, coronary heart disease and osteoporosis;
2 Community health service management and new information technology: implementation of electronic medical records/telemedicine, community health service management and construction of community medical information technology, information management of disease screening, etc;
3 The basic drug system and the use of drugs at the primary level;
4 Post-marketing evaluation studies of Chinese medicines: comprehensive clinical evaluation of proprietary Chinese medicines, pharmacovigilance, pharmacoeconomic evaluation, active monitoring, passive monitoring and other studies;
5 Real-world studies;
6 Evidence-based medicine and clinical epidemiology research.
Research Projects
1 Key Research Project on Modernization of Chinese Medicine, Key R&D Program of the Ministry of Science and Technology of China, "Evidence-based Evaluation of Ten Major Varieties of Chinese Patent Medicine and Classical Famous Formulas for the Treatment of Major Diseases after Marketing and Demonstration of Their Effect Mechanisms" (No.2018YFC1707400)
2 "Risk signal assessment based on monitoring data" (No.2015ZX09501004-001-002), a major new drug creation project of the Ministry of Science and Technology of China
3 "Clinical assessment of post-marketing safety risk signals and mechanism of Chinese medicine" (No.2015ZX09501004-001-009), a major new drug creation project of the Ministry of Science and Technology of China
4 "Early warning mechanism of postmenopausal osteoporotic fracture based on two models" (No.81373885)
5 "Research and development of ischemic stroke disease recurrence risk assessment system and demonstration application of Chinese medicine characteristic health management" (No.201507003-8) by the State Administration of Traditional Chinese Medicine
6 Beijing Science and Technology Program of Beijing Municipal Science and Technology Commission "Construction of Comprehensive Evaluation Index System of Beijing Traditional Chinese Medicine Hospital" (No.Z151100002115046)
Academic Achievements
[1] Zeng XY, Wang ZF, Lai YY, Zhang Q, Xie YM, Gao MH. Effectiveness study of real world Chinese deer melon polypeptide injection on renal function in fracture population[J]. World Traditional Chinese Medicine,2022,17(02):255-260.
[2] Song Zhuo, Xu Yun, Gong Lutian, Wang Zhifei, Xie Yanming, Wu Yu, Gao Rui, Yang Yufei. Reflections on the design of post-marketing clinical value re-evaluation studies of proprietary Chinese medicines using compound Agaricus syrup as an example[J]. New Drugs in Chinese Medicine and Clinical Pharmacology,2022,33(01):132-137.DOI:10.19378/j.issn.1003-9783.2022.01.019.
[3] Wei RL, Cui X, Xie YM. Pharmacoeconomic evaluation of applying TreeAge Pro to Qidong Yi Xin Oral Liquid for the treatment of viral myocarditis (Qi-Yin two deficiency evidence)[J]. Chinese Journal of Traditional Chinese Medicine,2022,47(03):829-835. doi:10.19540/j.cnki.cjcmm.20211115.501.
[4] Xie YANMING, Liu ZUANG, Jiang JJ, Wei XU, Shen H, Zhi YJ, Sun J, Li JY, Bao XXIA, Shi W, Zhang YIL. Clinical practice guidelines for postmenopausal osteoporosis in Chinese medicine (draft for comment)[J]. Chinese Journal of Traditional Chinese Medicine,2021,46(22):5992-5998.DOI:10.19540/j.cnki.cjcmm.20210709.501.
[5] Zhang Q, Wang ZF, Xie YM, Li YY, Wang LX, Liu XU, Geng HJ, Cui X, Liu FM, Sun CHQ, Wei RL, Zhang LD. Technical specifications for clinical comprehensive evaluation of proprietary Chinese medicines[J]. World Traditional Chinese Medicine,2021,16(22):3394-3397+3403.
[6] Cui X, Han S, Jin X, Wang ZF, Zhang Q, Xie YM. Comprehensive clinical evaluation of Danhong injection in the treatment of stroke (blood stasis and occlusion evidence) [J]. Chinese Journal of Traditional Chinese Medicine,2021,46(23):6096-6104.
[7] Zhang Q, Wang ZF, Xie YM, Li YY, Wang LX, Liu XU, Geng HJ, Cui X, Liu FM, Sun CHQ, Wei RL, Zhang LD. Specification for clinical comprehensive evaluation report of proprietary Chinese medicines[J]. Chinese Journal of Traditional Chinese Medicine,2021,46(23):6062-6067.DOI:10.19540/j.cnki.cjcmm.20210930.502.
[8] XI Junyu,Lv Jian,Xie Yanming. Systematic evaluation and Meta-analysis of the efficacy and safety of Xiangju capsule in the treatment of sinusitis[J]. Chinese Journal of Traditional Chinese Medicine,2022,47(02):537-546.
[9] Wang X, Zhang YIL, Sun K, Shen H, Qi BAOYU, Zhu LG, Xie YANM, Wei X. Screening for fall risk and associated factors among middle-aged and elderly residents in the community[J]. China Orthopaedic Injury,2021,34(12):1108-1113.
[10] Cui X, Wang LX, Liu GY, Xie YANM. The inspiration of international pharmacovigilance system on the establishment of pharmacovigilance system for traditional Chinese medicine[J]. Chinese Journal of Traditional Chinese Medicine,2021,46(21):5450-5455.
[11] Cheng, Feng, Jingming, Wang, Lianxin, Xie, Yanming. Visual analysis of CiteSpace scientific literature on kidney injury caused by Chinese medicine[J]. Chinese Journal of Traditional Chinese Medicine,2021,46(21):5475-5485.
[12] Lv J, Wang LX, Xie YM. Pharmacovigilance in Chinese medicine based on prescription sequence and prescription sequence symmetry analysis[J]. Chinese Journal of Traditional Chinese Medicine,2021,46(21):5468-5474.
[13] Shen H, Jiang Hongyan, Zhang Yili, Zhang Cheng, Zhi Yingjie, Sun Kai, Wang Xu, Fang Shengjie, Xie Yanming, Wei Xu. Correlation between Chinese medical evidence and bone metabolic markers in patients with osteoporosis[J]. Chinese Journal of Basic Chinese Medicine,2021,27(06):970-972+1046.